Oncoletter Interviews in cooperation with VJHEMONC
-
The Video Journal of Hematological Oncology (VJHemOnc, vjhemonc.com) is a global, open-access video journal, dedicated to providing trusted and up-to-date medical information in order to improve the awareness and understanding of hematological cancers.
Christian Buske:
Chemotherapy-free approaches in CLL, follicular lymphoma and DLBCL
2:31
Susan O’Brien:
Debate on the best first-line treatment for unmutated CLL: opinions from across the Atlantic
3:57
Brad Kahl:
ADCT-402 – a drug to watch
2:48
Sarah Huet:
Clinicogenetic risk models to predict outcome of follicular lymphoma patients
1:26
Won Seog Kim:
An overview on NK/T-cell lymphoma treatment
1:58
Won Seog Kim:
Biosimilars: Making biological agents availble worldwide
1:02
Ulrich Jager:
Diffuse large B-cell lymphoma lymphoma: Finding the best partner for durvalumab
2:49
Ulrich Jager:
Exploring and consolidating the CLL world
1:02
Ulrich Jager:
The current status of CLL treatment
3:26
Timothy Illdge:
The explosion of immuno-oncology
1:18
Timothy Illdge:
Combining radiotherapy and the immune system in lymphomas
2:49
Sattva Neelapu:
The pivotal ZUMA-1 trial for NHL
4:19
Graham Collins:
Personalising treatment to the biology of the NHL patient
2:38
Franco Cavalli:
The value of the ICML and highlights from the 2017 Annual Congress
2:19
Franco Cavalli:
What we can look forward to in the world of non-Hodgkin lymphoma
2:31
Bouthaina Dabaja:
Proton and photon therapy in managing hematological malignancies
3:15
Andrew Davies:
Key therapeutic advances in follicular lymphoma
4:02
Timothy Illdge:
Shifting the focus in lymphoma treatment
2:31
Sarah Huet:
Using models to predict progression in follicular lymphoma
1:01
Martin Fey:
The real cost of hematological cancer care explained
3:36
David Hodgson:
Reducing the risk of secondary malignancies in lymphoma
3:45
David Maloney:
Have novel drugs made stem cell transplantation obsolete?
1:13
David Maloney:
Immunotherapy highlights from ICML 2017
2:27
Christian Buske:
Comparing the efficacy and safety of CT-P10 to rituximab in advanced stages follicular lymphoma
2:53
Michael Wang:
A novel WINDOW of opportunity for young mantle cell lymphoma patients
2:23
Martine Bagot:
Escalating doses and improving outcomes in cutaneous T-cell lymphomas
1:24
George Follows:
Copanlisib produces promising results in relapsed/refractory follicular lymphoma
2:07
Christian Buske:
BGB-3111 and ibrutinib for Waldenström’s macroglobulinemia
2:48
Barbara Eichhorst:
Highlights from ICML 2017: The CLL2-BAG study
1:37
Christian Buske:
ICML 2017 session on the biosimilar rituximab: challenges and data
2:41
3:12
Andrew Lister:
Top follicular lymphoma discussion points at ICML 2017
3:28
Won Seog Kim:
Clinical evidence supporting rituximab
2:26
3:22
Graham Collins:
Tackling unmet needs in lymphoma
4:09
3:22
3:17
Laszlo Gulacsi:
Misconceptions about the use of biosimilars
1:23
1:01
1:30
3:18
2:06
Christian Buske:
Comparing the efficacy and safety of CT-P10 to rituximab in advanced stages follicular lymphoma
2:53
2:23
1:24
2:07
Christian Buske:
BGB-3111 and ibrutinib for Waldenström’s macroglobulinemia
2:48
Barbara Eichhorst:
Highlights from ICML 2017: The CLL2-BAG study
1:37
Christian Buske:
ICML 2017 session on the biosimilar rituximab: challenges and data
2:41
3:12
Andrew Lister:
Top follicular lymphoma discussion points at ICML 2017
3:28
Won Seog Kim:
Clinical evidence supporting rituximab
2:26
3:22
Graham Collins:
Tackling unmet needs in lymphoma
4:09
3:22
3:17
Laszlo Gulacsi:
Misconceptions about the use of biosimilars
1:23
1:01
1:30
3:18
2:06